N-甲基-N-(2-吡啶基)甘氨酸乙酯 | 1249006-32-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-甲基-N-(2-吡啶基)甘氨酸乙酯
• 英文名称: N-methyl-N-(pyridin-2-yl)glycine ethyl ester
• 英文别名: Ethyl 2-(methyl(pyridin-2-yl)amino)acetate；ethyl 2-[methyl(pyridin-2-yl)amino]acetate
• CAS: 1249006-32-3
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.233
• InChiKey: IJEMCRRHGXYEEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors
  申请人：——

  公开号：US20010031870A1

  公开（公告）日：2001-10-18

  The present invention is directed to aminoguanidine and alkoxyguanidine compounds, including compounds of Formula I: 1 wherein X is O or NH, L is —O— or —SO 2 —, and R 1 -R 4 , R 9 -R 19 , R a , R b , R c , Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing the compounds of Formula I. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage.

  本发明涉及氨基胍和烷氧基胍化合物，包括公式I的化合物：其中X为O或NH，L为—O—或—SO2—，R1-R4，R9-R19，Ra，Rb，Rc，Y，Z，n和m在规范中设置，以及其水合物，溶剂化物或药学上可接受的盐，可抑制蛋白酶酶如凝血酶。还描述了制备公式I化合物的方法。其中某些化合物通过直接选择性抑制凝血酶表现出抗血栓活性，或是用于形成具有抗血栓活性的化合物的中间体。本发明包括一种用于抑制哺乳动物中的血小板丢失、抑制血小板聚集、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于血液采集、血液循环和血液储存的设备制造材料中。
• Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
  申请人：Cytovia, Inc.

  公开号：US20030078292A1

  公开（公告）日：2003-04-24

  The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: 1 wherein R 1 -R 5 are defined herein. The present invention also relates to the discovery that compounds having Formula I-III are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled cell growth and spread of abnormal cells occurs.

  本发明涉及以通式I-III所表示的甘黄酸及其类似物和衍生物，其中R1-R5在此定义。本发明还涉及发现具有I-III式的化合物是caspase激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导细胞死亡，在各种临床病情中，不受控制的细胞生长和异常细胞的扩散。
• FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY
  申请人：Shenzhen Chipscreen Biosciences Co., Ltd.

  公开号：EP3560928A1

  公开（公告）日：2019-10-30

  The invention discloses a type of fused imidazole compound, preparation method and application thereof. The structure of the compound is shown in general formula I. The definition of each group therein is as described in the specification. These compounds are capable of selectively inhibiting indoleamine 2,3-dioxygenase (IDO). The compounds can act as an IDO inhibitor for treating and/or preventing a disease having a pathological feature with IDO-mediated tryptophan metabolic pathways, for example, cancer, eye disease, autoimmune disease, psychological disorder, depression symptom, anxiety disorder and other diseases.

  本发明公开了一种融合咪唑化合物及其制备方法和应用。该化合物的结构如通式 I 所示。其中各基团的定义如说明书所述。这些化合物能够选择性地抑制吲哚胺 2,3-二氧化酶（IDO）。这些化合物可作为 IDO 抑制剂，用于治疗和/或预防具有 IDO 介导的色氨酸代谢途径病理特征的疾病，例如癌症、眼病、自身免疫性疾病、心理障碍、抑郁症状、焦虑症和其他疾病。
• Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
  申请人：SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.

  公开号：US10604529B2

  公开（公告）日：2020-03-31

  The invention discloses a type of fused imidazole compound, preparation method and application thereof. The structure of the compound is shown in general formula I. The definition of each group therein is as described in the specification. These compounds are capable of selectively inhibiting indoleamine 2,3-dioxygenase (IDO). The compounds can act as an IDO inhibitor for treating and/or preventing a disease having a pathological feature with IDO-mediated tryptophan metabolic pathways, for example, cancer, eye disease, autoimmune disease, psychological disorder, depression symptom, anxiety disorder and other diseases.

  本发明公开了一种融合咪唑化合物及其制备方法和应用。该化合物的结构如通式 I 所示。其中各基团的定义如说明书所述。这些化合物能够选择性地抑制吲哚胺 2,3-二氧化酶（IDO）。这些化合物可作为 IDO 抑制剂，用于治疗和/或预防具有 IDO 介导的色氨酸代谢途径病理特征的疾病，例如癌症、眼病、自身免疫性疾病、心理障碍、抑郁症状、焦虑症和其他疾病。
• [EN] FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY<br/>[FR] COMPOSÉ IMIDAZOLE FUSIONNÉ AYANT UNE ACTIVITÉ INHIBITRICE DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE<br/>[ZH] 具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
  申请人：SHENZHEN CHIPSCREEN BIOSCIENCES LTD

  公开号：WO2018113624A1

  公开（公告）日：2018-06-28

  公开了一类稠合咪唑化合物、其制备方法及其应用。所述化合物的结构如通式I 所示，其中各基团的定义如说明书所述。这些化合物能够选择性地抑制吲哚胺2,3-双加氧酶(IDO)。所述化合物可作为IDO抑制剂用于治疗和/或预防具有IDO介导的色氨酸代谢途径的病理学特征的疾病，例如癌症、眼部疾病、自身免疫性疾病、心理障碍、抑郁症、焦虑症及其它疾病。